White House unveils nine more ‘most favored nation’ dealsnews2025-12-19T19:19:36+00:00December 19th, 2025|Endpoints News|
Galapagos’ last asset posts mixed results as future remains in fluxnews2025-12-19T17:02:27+00:00December 19th, 2025|Endpoints News|
BioMarin to pay $4.8B for Amicus and its rare disease drugsnews2025-12-19T16:10:45+00:00December 19th, 2025|Endpoints News|
Senators point fingers over who blocked the rare disease voucher reauthorizationnews2025-12-19T15:43:21+00:00December 19th, 2025|Endpoints News|
Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 failnews2025-12-19T15:41:31+00:00December 19th, 2025|Endpoints News|
Joe Jimenez’s Aditum goes to Fosun for major biobuck-loaded collaborationnews2025-12-19T13:15:31+00:00December 19th, 2025|Endpoints News|
Catalent handed two Form 483s for Maryland gene therapy sitesnews2025-12-19T12:25:40+00:00December 19th, 2025|Endpoints News|
Endpoints at JPM 2026: What we’ll be talking aboutnews2025-12-19T12:00:27+00:00December 19th, 2025|Endpoints News|
Novo obesity partner nabs Pfizer vet as CBO; CureVac’s leadership clears out as BioNTech takes overnews2025-12-19T12:00:17+00:00December 19th, 2025|Endpoints News|
US commission urges action as China’s biotech sector advancesnews2025-12-19T05:01:37+00:00December 19th, 2025|Endpoints News|
